Live News Categoriesmarket

MAIA.A (MAIA.A) News

Follow MAIA.A (MAIA.A) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MAIA.A Asset market Sector Markets 90 days 1 Updated Oct 07, 2026, 12:15 PM UTC Open live news feed

H Maia Biotech completes Phase 2 enrollment for THIO-101 ateganosine plus cemiplimab Maia Biotechnology said Phase 2 enrollment is complete for the ateganosine plus cemiplimab cohort in THIO-101, with THIO-104 Phase 3 enrollment at 65% of a 100-patient year-end goal; an interim analysis is planned for 20 EARNINGS | Oct 07, 2026, 12:15 PM UTC